0.93
-0.085(-8.42%)
Currency In USD
| Previous Close | 1.01 |
| Open | 0.95 |
| Day High | 0.98 |
| Day Low | 0.92 |
| 52-Week High | 7.5 |
| 52-Week Low | 0.62 |
| Volume | 409,607 |
| Average Volume | 423,955 |
| Market Cap | 17.18M |
| PE | -0.7 |
| EPS | -1.33 |
| Moving Average 50 Days | 1.03 |
| Moving Average 200 Days | 1.72 |
| Change | -0.09 |
If you invested $1000 in BioVie Inc. (BIVI) since IPO date, it would be worth $9.26 as of July 01, 2025 at a share price of $0.925. Whereas If you bought $1000 worth of BioVie Inc. (BIVI) shares 3 years ago, it would be worth $67.03 as of July 01, 2025 at a share price of $0.925.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
GlobeNewswire Inc.
Jun 26, 2025 12:00 PM GMT
Hybrid, decentralized trial of bezisterim in early Parkinson’s Disease prioritizes patient access and participationCARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
GlobeNewswire Inc.
Jun 24, 2025 8:05 PM GMT
CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advance
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
GlobeNewswire Inc.
May 15, 2025 12:00 PM GMT
Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog Evidence suggests sustained inflammation plays a central role in the